Combination of MUC1 and MUC4 expression predicts clinical outcome in patients with oral squamous cell carcinoma

Yoshiaki Kamikawa, Yuji Kanmura, Tomofumi Hamada, Norishige Yamada, Muzafar A Macha, Surinder Kumar Batra, Michiyo Higashi, Suguru Yonezawa, Kazumasa Sugihara

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Both MUC1 and MUC4 are high molecular weight glycoproteins and are independent indicators of worse prognosis in many human epithelial cancers including oral squamous cell carcinoma (OSCC). However, there has been no investigation of the clinical importance of the co-expression of MUC1 and MUC4 in OSCC. The aim of this study was to evaluate the co-expression profile of MUC1/MUC4 and analyze the prognostic significance in OSCC. Methods: We examined the expression profile of MUC1 and MUC4 in OSCC tissues from 206 patients using immunohistochemistry. The co-expression profile of MUC1/MUC4 and its prognostic significance in OSCC was statistically analyzed. Results: MUC1 and MUC4 overexpression were strongly correlated with each other (p < 0.0001) and a combination of both MUC1 and MUC4 expression was a powerful indicator for tumor aggressiveness such as tumor size (p = 0.014), lymph node metastasis (0.0001), tumor stage (p = 0.006), diffuse invasion (p = 0.028), and vascular invasion (p = 0.014). The MUC1/MUC4 double-positive patients showed the poorest overall and disease-free survival. Multivariate analysis revealed that MUC1/MUC4 double-positivity was the strong independent prognostic factor for overall and disease-free survival (p = 0.007 and (p = 0.0019), in addition to regional recurrence (p = 0.0025). Conclusions: Taken together, these observations indicate that the use of a combination of MUC1/MUC4 can predict outcomes for patients with OSCC. This combination is also a useful marker for predicting regional recurrence. MUC1 and MUC4 may be attractive targets for the selection of treatment methods in OSCC.

Original languageEnglish (US)
Pages (from-to)298-307
Number of pages10
JournalInternational Journal of Clinical Oncology
Volume20
Issue number2
DOIs
StatePublished - Apr 1 2015

Fingerprint

Squamous Cell Carcinoma
Disease-Free Survival
Recurrence
Neoplasms
Mouth Neoplasms
Blood Vessels
Glycoproteins
Multivariate Analysis
Molecular Weight
Lymph Nodes
Immunohistochemistry
Neoplasm Metastasis

Keywords

  • Immunohistochemistry
  • MUC1
  • MUC4
  • Oral squamous cell carcinoma
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Surgery
  • Hematology

Cite this

Combination of MUC1 and MUC4 expression predicts clinical outcome in patients with oral squamous cell carcinoma. / Kamikawa, Yoshiaki; Kanmura, Yuji; Hamada, Tomofumi; Yamada, Norishige; Macha, Muzafar A; Batra, Surinder Kumar; Higashi, Michiyo; Yonezawa, Suguru; Sugihara, Kazumasa.

In: International Journal of Clinical Oncology, Vol. 20, No. 2, 01.04.2015, p. 298-307.

Research output: Contribution to journalArticle

Kamikawa, Y, Kanmura, Y, Hamada, T, Yamada, N, Macha, MA, Batra, SK, Higashi, M, Yonezawa, S & Sugihara, K 2015, 'Combination of MUC1 and MUC4 expression predicts clinical outcome in patients with oral squamous cell carcinoma', International Journal of Clinical Oncology, vol. 20, no. 2, pp. 298-307. https://doi.org/10.1007/s10147-014-0710-6
Kamikawa, Yoshiaki ; Kanmura, Yuji ; Hamada, Tomofumi ; Yamada, Norishige ; Macha, Muzafar A ; Batra, Surinder Kumar ; Higashi, Michiyo ; Yonezawa, Suguru ; Sugihara, Kazumasa. / Combination of MUC1 and MUC4 expression predicts clinical outcome in patients with oral squamous cell carcinoma. In: International Journal of Clinical Oncology. 2015 ; Vol. 20, No. 2. pp. 298-307.
@article{d56ff2f7ccec42aa855ae8bcb87c806a,
title = "Combination of MUC1 and MUC4 expression predicts clinical outcome in patients with oral squamous cell carcinoma",
abstract = "Background: Both MUC1 and MUC4 are high molecular weight glycoproteins and are independent indicators of worse prognosis in many human epithelial cancers including oral squamous cell carcinoma (OSCC). However, there has been no investigation of the clinical importance of the co-expression of MUC1 and MUC4 in OSCC. The aim of this study was to evaluate the co-expression profile of MUC1/MUC4 and analyze the prognostic significance in OSCC. Methods: We examined the expression profile of MUC1 and MUC4 in OSCC tissues from 206 patients using immunohistochemistry. The co-expression profile of MUC1/MUC4 and its prognostic significance in OSCC was statistically analyzed. Results: MUC1 and MUC4 overexpression were strongly correlated with each other (p < 0.0001) and a combination of both MUC1 and MUC4 expression was a powerful indicator for tumor aggressiveness such as tumor size (p = 0.014), lymph node metastasis (0.0001), tumor stage (p = 0.006), diffuse invasion (p = 0.028), and vascular invasion (p = 0.014). The MUC1/MUC4 double-positive patients showed the poorest overall and disease-free survival. Multivariate analysis revealed that MUC1/MUC4 double-positivity was the strong independent prognostic factor for overall and disease-free survival (p = 0.007 and (p = 0.0019), in addition to regional recurrence (p = 0.0025). Conclusions: Taken together, these observations indicate that the use of a combination of MUC1/MUC4 can predict outcomes for patients with OSCC. This combination is also a useful marker for predicting regional recurrence. MUC1 and MUC4 may be attractive targets for the selection of treatment methods in OSCC.",
keywords = "Immunohistochemistry, MUC1, MUC4, Oral squamous cell carcinoma, Prognosis",
author = "Yoshiaki Kamikawa and Yuji Kanmura and Tomofumi Hamada and Norishige Yamada and Macha, {Muzafar A} and Batra, {Surinder Kumar} and Michiyo Higashi and Suguru Yonezawa and Kazumasa Sugihara",
year = "2015",
month = "4",
day = "1",
doi = "10.1007/s10147-014-0710-6",
language = "English (US)",
volume = "20",
pages = "298--307",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Combination of MUC1 and MUC4 expression predicts clinical outcome in patients with oral squamous cell carcinoma

AU - Kamikawa, Yoshiaki

AU - Kanmura, Yuji

AU - Hamada, Tomofumi

AU - Yamada, Norishige

AU - Macha, Muzafar A

AU - Batra, Surinder Kumar

AU - Higashi, Michiyo

AU - Yonezawa, Suguru

AU - Sugihara, Kazumasa

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background: Both MUC1 and MUC4 are high molecular weight glycoproteins and are independent indicators of worse prognosis in many human epithelial cancers including oral squamous cell carcinoma (OSCC). However, there has been no investigation of the clinical importance of the co-expression of MUC1 and MUC4 in OSCC. The aim of this study was to evaluate the co-expression profile of MUC1/MUC4 and analyze the prognostic significance in OSCC. Methods: We examined the expression profile of MUC1 and MUC4 in OSCC tissues from 206 patients using immunohistochemistry. The co-expression profile of MUC1/MUC4 and its prognostic significance in OSCC was statistically analyzed. Results: MUC1 and MUC4 overexpression were strongly correlated with each other (p < 0.0001) and a combination of both MUC1 and MUC4 expression was a powerful indicator for tumor aggressiveness such as tumor size (p = 0.014), lymph node metastasis (0.0001), tumor stage (p = 0.006), diffuse invasion (p = 0.028), and vascular invasion (p = 0.014). The MUC1/MUC4 double-positive patients showed the poorest overall and disease-free survival. Multivariate analysis revealed that MUC1/MUC4 double-positivity was the strong independent prognostic factor for overall and disease-free survival (p = 0.007 and (p = 0.0019), in addition to regional recurrence (p = 0.0025). Conclusions: Taken together, these observations indicate that the use of a combination of MUC1/MUC4 can predict outcomes for patients with OSCC. This combination is also a useful marker for predicting regional recurrence. MUC1 and MUC4 may be attractive targets for the selection of treatment methods in OSCC.

AB - Background: Both MUC1 and MUC4 are high molecular weight glycoproteins and are independent indicators of worse prognosis in many human epithelial cancers including oral squamous cell carcinoma (OSCC). However, there has been no investigation of the clinical importance of the co-expression of MUC1 and MUC4 in OSCC. The aim of this study was to evaluate the co-expression profile of MUC1/MUC4 and analyze the prognostic significance in OSCC. Methods: We examined the expression profile of MUC1 and MUC4 in OSCC tissues from 206 patients using immunohistochemistry. The co-expression profile of MUC1/MUC4 and its prognostic significance in OSCC was statistically analyzed. Results: MUC1 and MUC4 overexpression were strongly correlated with each other (p < 0.0001) and a combination of both MUC1 and MUC4 expression was a powerful indicator for tumor aggressiveness such as tumor size (p = 0.014), lymph node metastasis (0.0001), tumor stage (p = 0.006), diffuse invasion (p = 0.028), and vascular invasion (p = 0.014). The MUC1/MUC4 double-positive patients showed the poorest overall and disease-free survival. Multivariate analysis revealed that MUC1/MUC4 double-positivity was the strong independent prognostic factor for overall and disease-free survival (p = 0.007 and (p = 0.0019), in addition to regional recurrence (p = 0.0025). Conclusions: Taken together, these observations indicate that the use of a combination of MUC1/MUC4 can predict outcomes for patients with OSCC. This combination is also a useful marker for predicting regional recurrence. MUC1 and MUC4 may be attractive targets for the selection of treatment methods in OSCC.

KW - Immunohistochemistry

KW - MUC1

KW - MUC4

KW - Oral squamous cell carcinoma

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84939882458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939882458&partnerID=8YFLogxK

U2 - 10.1007/s10147-014-0710-6

DO - 10.1007/s10147-014-0710-6

M3 - Article

VL - 20

SP - 298

EP - 307

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 2

ER -